Tauopathies - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Tauopathies - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 54-page report is available in PDF from $2000.

Tauopathies - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Tauopathies - Pipeline Review, H1 2015’, provides an overview of the Tauopathies’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tauopathies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tauopathies and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Tauopathies
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Tauopathies and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Tauopathies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tauopathies pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tauopathies Overview 7
Therapeutics Development 8
Pipeline Products for Tauopathies - Overview 8
Pipeline Products for Tauopathies - Comparative Analysis 9
Tauopathies - Therapeutics under Development by Companies 10
Tauopathies - Therapeutics under Investigation by Universities/Institutes 11
Tauopathies - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Tauopathies - Products under Development by Companies 14
Tauopathies - Products under Investigation by Universities/Institutes 15
Tauopathies - Companies Involved in Therapeutics Development 16
AbbVie Inc. 16
Bristol-Myers Squibb Company 17
Chronos Therapeutics Limited 18
Prothena Corporation plc 19
Selvita SA 20
SK Biopharmaceuticals Co., Ltd. 21
Summit Therapeutics plc. 22
Tauopathies - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Drug Profiles 31
Antibody to Target Tau Protein for Alzheimer's Disease and Tauopathies - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BMS-986168 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Gene Therapy for Tauopathies - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibodies to Inhibit Tau for Alzheimer's Disease and Tauopathies - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RDC-5 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SEL-141 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule for Tauopathies and Alzheimer's Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules for Alzheimer's Disease and Tauopathies - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Inhibit PAR-1 for Neurodegenerative Diseases - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit Tau for Alzheimer Disease and Tauopathies - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Thiamet-G - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress…

For more information open Tauopathies - Pipeline Review, H1 2015.


Original Article: Tauopathies - Pipeline Review, H1 2015


More From BioPortfolio on "Tauopathies - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...